Item 8.01 Other Events.

On January 19, 2022, Immix Biopharma, Inc. announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
99.1            Press release dated January 19, 2022




  -2-

© Edgar Online, source Glimpses